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Studies r eporting a high concentration of WR-2721 in mouse sal ivary gl ands led to ou r stud i es of possible r a dioprot e ction of these
glands by t his d rug f rom ionizing r adiation .

Or al effects of radiation

in the presence of \<R- 2721 were s tudied in mice and doge .

Histo logi cal

evaluation of mouse salivary glands irradiated with 1000 rads of 60 Co
showed essen tially no difference bet ween cont ro l and experime ntal
animals .

Almost full regeneration of t he sero us sal ivary compone nt s

occu rred by 6 months i n both groups and nei ther group had changes in
the mucous glands .

The use of higher doses o f radiation in th e mouse

was prevented by the oral cavit y death syndrome (LD50/ B-IO) whic h was
r educed by a factor of 2.1 when WR- 2721 was given 30 minutes before irradiation of the head.

Salivary function in mongr el dogs measured at

weekl y int ervals fo r one month following rad ia t ion s howed no significan t
difference in control and experimental

anin~15;

therefore the salivary

gland may be an organ capa ble of metabolizing or exc r eting of \<R-272 l.
Ma r ked protec tion from ac ute radia tion damage of the skin and o r a l
mucosa was observed in dogs receiving WR-2721 prior t o treatment with

radiation.
st ruc tures .

A dose modifying facto r of 1.67 was obtained for these
If s uch normal tissue sparing could be ach i eved clinically,

higher doses of radiation could be used in treatment of head and neck
malignancies, thereby increasing the probability for s uccess f ul radiation therapy for such tumors.

INTRODUCTION
Cancer, characterized by potential i nvasion of healthy tissues,
metastases to other parts of the body, and unlimited cell growth, is

the second leading cause of death in the United States .

In 1971, fo r

example , 17.5 per cent of all deaths was due to cancer (4).

Cancer is a lso a major cause of death throughout the world.

Sur-

vival rates for individuals with various types of cancer have been increased .

The surv ival rate increase for individuals with some types of

cancer has been striking , while in others, the survival r a tes have de-

creased or leveled off.

The survival rates for i ndividuals with

certain forms of cancer have shown no change during the past twenty-

five years.

There hns been an ove rall decrease in cancer incidence and

morcality, but some types of cancer (e. g ., lung, pancreas, colon,
prostate, and bladder) have

incr~ased.

Recent signif i cant progress in the area of cancer treatment can be

explain ed by three fac t ors: (1) diagnosis of the disease in a n early
localized state, (2) treatment of the cance r within four mon t hs of
diagnosis, and (3) development of new diagnos tic and therape utic techniques and devic es .

It should be noted that, even with the new ad-

vances, many curable patients will contiIlue to die of cancer

be~ a use

they escaped early detection and cannot benefit from modern therapy
when their diseases are in early stages.

As new diagnostic and thera-

peutic methods are deve loped and us e d, trc.11 s in treatment plans change.
In the treatment of breast cancer, for example, survival rates recorded
1

2

during the period from 1950-1959 have been significantly improved (4) .
Since the 1950's, patients have received less surgical treatment and
mo~e adjuvant therapy with radiation, chemotherapy, and /or hormones .

This study is limit ~

~o the investi gation of radiation effects

related to radiotherapy o f he ad and neck cancers .

Nedical care is

concerned primarily with patient support during and after the stress
of treatment in patients with head and ne ck cancers .

A careful medical

history and physical examination should be performed as an aid in providing the bes t medical ca re possible.

During the course of patient

exami.nHion a ll bodily functions s hould be considered by the physician.
Pulmonary function and cardiac status, for example , should be carefully
e valuated and current and/or pa s t medical or surgical diseases should

be noted.

All these factors play an important role in deciding which

treatment plan will be followed.

When i t has been determined that

radio therapy is applicable as a therapeutic means, a trea tment plan

is made out which may leq uire tha t the patient be treated with 60 007000 rads (radiation absorbed dose ) of 60Co therapy delivered in fractionated doses over a period of six to seven weeks .
Figure I shows, for example, a 52-year-old male patient who developeo an e pidermoid car~inoma of the anterior tongue.

Figure 2

shows the same patient six weeks later after he had received 6000 rads
of 60 Co therapy through bilaterally opposed ports.
results were lis ted as satisfactory.

The therapeutic

Skin cancers detected early

usually require less total radiation for successful trea tment.

Figure

3 is a photograph of a patien t who developed squumous carcinoma of the
skin.

The treatment of this patient consisted of 5500 rads of 60 Co

therapy delivered through a single lateral field over a per od of five

3

Figure 1.

52-year-old male pat ient wi th an epidermoid carcinoma of t he
Courtesy of Department of Radiation
Medicine, University of Kentucky Medical Center.
anterior tongue.

Figure 2 .

Same 52-year-old male patient six weeks following eradication
of the epidermoid carcinoma with 6000 rads of 60 Co therapy.
Courtesy of Depa rt men t of Radiation Medicine, University of
Kentucky Medical Center.

;

I

;

\
-

4

Figure 3.

~~le

patient with a pre-auricular squamous carcinoma.

Courtesy of Department of Radiation Medicine, University of
Kentucky Medical Center.

Figure 4.

Same male pat1ent five weeks following eradication of the
ca rcinoma with 55LO rads of 60Co therapy. Only a small
pre-auricular ulcer remains.

Courtesy of Department of

Radia tion Medicine, University of Kentucky Medical Center.

5

weeks.

Figure 4 is a photograph of this patient taken after therapy

for the cancer was completed.

An OPtimal selective effect i n radiotherapy is reached when the
tumor is complet e

1
.,

destroyed wi thout significant functio nal or

structural injury co t he sur ro unding normal tiss ue.
POinted ou t tha t a

c~rta in

It should be

amo unt of damage t o the normal tissue mus t

usually be a c cepte d a l ong wi th the erad ica tion of the malignancy, as a
truly selective effec t is not very often reached.

Since radiation spa r es no biologica l structure , the amo unt of radia tion a dministered must be limited both in volume of tiss ue treat ed as
well as in rota l dose during r a diotherapy.

The therapeu tic ratio must

be Conside red in order to ke ep the normal tissue injury at a minimum
a nd st ill give an effective tumor dose.

The therapeutic ratio i s de-

fined as the relationship between th e tumo r lethal dose and normal
tissue tolerance (19).

Radiotherapy i s limited by this the r a peutic

ratio because no radiation effec t is selective for the mal i gnancy alone .
Further st udies dea ling with the modification of the the rapeutic ratio
will therefore be likely to yield useful information.

McJification of

the therapeutic ratio might for example permit c uring of non-curable
malignancies beca use highe r doses of r a diation could be used.

A use ful

mOdi ficatio n of the therapeu tic ratio Could res ult from the use of agents
which could protect the normal tissues while providing no protection to
the cancerous tiss ue s .

Chemicals that act as radiosens itizers and radiopro tectors are
known.

Radios enSitizing agents enhance the rad1ation effects, whereas

radioprotecting agents prOvide an apparent protection against the
effects of radiation .

These agents tend to have similar eff ects upon

6

normal and

rr~lignant

tis sues .

An agent which could simultaneously

protect th E normal tissues and sensitize the malignant ce lls would be
most useful, bu t no such agen t is known .

The presen t study is con-

cerned wi th a • ' .g, S- 2-(3-ami nop ropylamino)ethyl phos phorothioate

"'hlc~

(l1R-27 21).

has been shown to protect normal ti ss ues but not the

malignanl'" one.":> ( 17) .

This di ffere ntial protec tion may be due, in par t,

to dif f e rent c oncentrations of th e drug in the healthy a nd malignant
ti ssue$.

The purpo se ot t hi s s tud y is to evaluate the radioprotection

a ffo rd eu by this J rug to head and neck structures in do gs and mice.
Uecause high concen tra tion s of this drug have been demonstrated in the
salivary g lands of mice, the present investiga tion evaluating the radioprotection affo rded by this compound can indicat e whether or not the
compound has potential for use in radiation therapy of cancers .

Significant cont ri butions to the knowledge of radiation effect s
have been made through the studies on compounds which modify ionizing
radia tion.

Bee t- use of the severe toxicity which was produced in animal

sys t ems, early studies on radiopro t ecto r s were disappointing .

The re-

birth of interest in radiop rot ection i n the United States can pr obably
be accounted for by the discovery of a thiophosphate compound (WR-2721)
which was found t o ryrovide protection to normal tissues but not to
cancerous tissues in a tumor-bearing mouse following radiation (30) .
Thiophospha tes
radioprotection .

have been the major compounds inves t igated for a rol e in
The mo s t prominent of these radioprotectors a re

listed in Ta ble I (II).
The phospho rothioate rad i oprotective agents were first synthesized

in 1959 (1) .

Later studies showed that these agents protec.t against

ionizing radiation (2, 10, 28).

Recent studies indicate that the new

TABLE I
MOST PROMINENT THIOPH05PHOROTHIOATE RADIOPROTECTIVE CO~~OUNDS
Designation/Name of Compound

MEA

Struc ture

8- mercaptoethylamine (cysteamine)

o
WR-2529

3- (2-mercaptoethylamino)propionamide p-toluenesulfonat e

WR-2721

S-2-(3-aminopropylamino) e thy l phosphorothioc acid hydrate

WR-2823

S-2-(5-aminopenty lamino)ethyl phosphorothioc acid monohydrate

WR- 638

Sodium hydrogen S- (2- aminoethy l )phosphorothioate

•

HSCH/, rl l HCH2CH 2CNII 'CH C6H 450 3H
2
3

8

radioprote ctive pho s phoro t hioate compounds a r e l e ss to x ic than th e

previously s tudied radiopro t e ctors .

WR- 272l has been "hown to give

t he grea t es t prot ec tio n o f a ny of these compo unds (1 2 , 17),

WR- 2721 has been s howr

:0

Be caus e

pr ovide a high degree of pro t e ct i on in

s eve ral no rmal tissues while providin g only minima l pro t ec tion f or

tumors) it has become a s i gni fican t d rug fo r use in s tudi es o f radio-

protection.

The toxic ity produce d by this drug i s within a n acceptable

range .

The pr ocess by which WR-2 72l ent e r s the c e ll ha s been de s cribed (27).
Upon entry i nto the

~e ll,

the compo und becomes dephos pho rylat e d

matically , thus exposing the s ulfhydry l g r o up.

~nzy

It i s tho ught that this

proces s occurs f ast enough that no intact t<R- 27 21 i s left inside the
c e ll.

Norma l cells and tumor cells show identical c e ll me mbrane perme-

ability to this drug , and bo th ce ll types readily dephosphorylate th e
compound.

However, since the drug enters the c e l l by pas sive diffusion,

less absorption would be expected to occur in a solid tumo r because the
tumor is poorly vas c ulariz e d.

This preve nt s ce livery of large concen-

trations of WR-27 21 to the tumor cells (1 2).
The mechani s m by wh i ch WR-2721 pro t ec t s t he ce ll fr om radiation i s
not certain.

It i s thought that it may work by the same mechanism(s)

propo s ed f or all sulfhydryl radioprotec tors (7): ( 1) removal of free
radical s f ormed by radiation, (2) repair by donation of hydrogen atoms,
(3) intera c tion with ce llular pro teins, (4) production of hypoxia in
the tiss ues, and/or (5) delay of cellular division or inhibition of
mitosis.
I~

the mechanism is by free radical removal, then it is suggested

that fre e radicals produced by radiation, such as the hydroxyl radica l,

9

oxidize the protective :j.gent, the refote fo rming a resonance-stable

free radical which is not capable of reacting with the cellular companents.

If the free radicals act as oxid izing agents they are there-

preven ~ p

fore

from r eac tin g with cellular components.

It was found

that the oxida t ion of radioprotectors, including WR-272l, indicates
that they are capab l e of reacting with the r adicals which are produced

by the radiation (15).
It i s possible that the prot ec tive agent can donate a hydrogen atom
to a molec ule which was conve rted to a free radical by radiation.

Thus

t he injured mo l ecule would be restored to its original or normal state

upo n ac ceptance of the hydrogen atom (6) .
If the protective agent reacts with cellular proteins, the free

sulfhydryl groups could form mixed disulfide bonds with the sulfhydryl
groups of the proteins.

Upon attack by a radiation-induced free

radical, one sulfur atom of the disulfide is oxidized while the other
is reduced.

Consequently, the protein is not damaged by radiation.

This mode of action is illustrated in Table I I .

It should be noted

that the protein could be oxidized which would leave the protein
altered .

This alternative route would allow for only 50 per cent of the

radic.a l interactions to damage proteins, hen ce leaving 50 per cent of

the proteins protected from t his type of o xidation (7) .
The damaging effects of radiation are enhanced in the presence or
oxygen, and a state of hypoxia provides protection from the radiat!on.
Since thiol compounds are very easily oxidized, it has been theorized
tha t tissue oxygen would be used up during such oxidations, hence

leaving a state of hypoxia.
theory (29).

.

One investigation tended to support this

This study showed that upon injection of WR-272l

".

-

10

TABLE II
POSSIBLE RADIOPROTECTIVE MECHANISM WITH MIXED DISULFIDE FORMATION

~H2
I

R

I
I
S
I
PROTEIN
S

SII
(~lixed

(Radical)

Disulfide)

..

+

I

PROTEIN

NH2

I
I
S
I
S

R

NH2

I
I

R

PROTEIN
(Radioprot e ctor)

+

I

SH

SH

(Mixed Disulfide)

I

PROTEIN

ALTERNATIVE ROUTE

NIH2
R

J
I

S

I

NH2

(Mixed Disulfide)

(Radical)

..

I
I

R

+

S02

I

PROTEIN

SH

PROTEIN

Oxidation of proteins t akes place when this alternative route occurs.

11

vasodilation is produced and 1s prominent in the spleen .

The vaso-

dilation of the spleen alters the blood supply to the rest of the body
and does so in such a way as to reduce tissue oxygen tensions and
thereby elevates

r~ · ; r.~ i on

resistance.

It was pointed Qut that vaso-

dilation may be a un i versa.l effect of 1-'R-2721, but i f this is so, it
should not prevent the use of 1-'R-272l in radiotherapy in man.

In the

event vasodilation does not take place , a larger amount of WR-2721
would be expected to be tolerated.
If t he mechanism involves a delay in cell division, there may be
more time available for repair of damage caused by radia tion.

If the

lTIechanism invo l 'Jes mitotic inhibition, it co uld be in such a way as to

ar rest the cells in a radioresistant stage, therefore providing protection from the radiation.
Because there a re exceptions to all the above mechanisms, the

radioprotection provided by WR- 272l probably results from a combination
of severa l mechanisms .

There are , for example , compounds which form

disulfides but give no protection (7).
unrelated. to hypoxia (7).

CysteQmine has shown protection

There a re molecules with functional group

distributions in structures similar t o those in the resonance-stab le

free r adicals formed by radioprot ec tors which do no t give protection (7).
Hore r esearch i s needed before the me chanism or mechanisms through which
protection is afforde d can be explained adequately .

Hetabolism st udies in rat s ( 22) have indicated that the main excretion of

~~-272l

occurs through the feces.

route for excretion i s in the urine.

The second most important

About 74 per cent of the total

drug administered was excreted durin g the first 24 hours following oral
administration of

~~-272l

and about 94 per cent after 48 hours.

Only

12

about 6 per cent waB retained.

It was found that about 1.35 per cent

of the tot al drug re tained was c oncentrat e d in the s elec ted organs
(e . g., e yes , brain, hea rt . lung , liver, kidne y , sp l een), 0 . 09 per cent

by the

I"

o,d. 0 .01 pe r cent by the muscle, 0.02 per cent by the fat,

1 ~9 per cent by t he gas tro inte s tinal tract, and 3 . 31 per cent by the

carc ass

.'::'\l d

r emaining vis c e ra.

Observa tions of the excretory products

during t he 48 hours followin g administration showed both the urine and
fec e s to be of normal c o lor and consistency.

Autopsy of the animals

a fter 48 hours showed all organs to be normal except the lungs of one

animal (a total of three was used) which appeared spl.otchy in color.
A second study (23) was done usin g twice the amount of "~-272l per gram
of body weight with e s sentia lly the same results as those listed above.
The studies mentioned above reported that the drug crosses the
blood-brain barrier, but that the amount crossing the barrier was less

than 0.01 per cent of the total amount administered to the animal.
This figure included the combined amounts whi ch enter the eyes and
brain.

In a recent study, it war report e d that the brain, one hour

following intravenous inJ~ction of WR-272l shows very little concentration of the drug (25).

An earlier study reports that the drug

WR-272l does not cross ove r the blood-brain or placental barriers (20).
However, radioactivity wa s reported around the cerebral blood vessels

and choroid plexus.

Neve rtheless, this radioactivity seemed to be very

low.

High localization of WR-272l has been reported in the hematopoietic
tissues, gastrointestinal and urinary tracts, and in some glandular
tissue with maximum concentrations in the tissues between 1-4 hours

following admin ~stration (20).

The blood appears to be cleared of the

13

drug within 5 minutes.

The major si t e of me t abolism of the drug seema

to be the live r with most of the elimination of the drug taking place
via the gastrointestinal a nd urina ry tracts within 48 hours following

administration .
Th e main route of excret ion of \ofR-27 21 seems t o be via the gast ro-

intestinal and urinary trac ts.

The live r s hows high concentrations of

the drug, and it appears to be the area of greatest metabolism of the

drug .

Other sites of high concentrations include the hematopoietic

tissues and glandular tissues .

The submandibular salivary gland had

been shown to have a great densit y of the drug (25).
Autonomic and acute ca rdiovascular effec t s of lVR-2721 have been

found to be slight with cumulative intravenous doses of up to 600mg/kg .
These effects were studid in cats and dogs (5).

Only small increases

in femoral blood flow were produced by 1<R- 2721 whereas a similar
phosphorothioate produced a marked increase .
blood pressure of 5-15

mID

A slight depress ion in

Hg was noted which lasted for 5 minu t e s but

was followed by a gradual increase of 30-40 mm Hg .

A depression of

15-30 heart beats pe r minute was ob tained from WR- 2721 .

The carotid

a rtery occlusion pressor response was reduced by WR-2721 thirty minutes
following injection, whereas it was not reduced by the other similar
phosphor o thioat es .

Lower doses (one-half as much) of the other

phosphorothioates produced much greater depressive effects which lasted
for longer periods of time.

This indicates that WR- 2721 is not as toxic

as similar phosphorothtoates.
Indications that WR-2721 may ac t as a ganglionic blocking age nt
are evidenced by its ability to differentially block the effects of preganglionic nerves leaving the post-ganglionic nerves unstimulated.
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Other effects noted from WR-2721 injection i nclud pd slight mydriasis
and a watery type salivation.

Duri ng the course of rad io th e rapy of he ad and neck cancers, complications may be in troduced

'_J"

, h are associated with the skin, mouth

and throat , and salivary gl and s (15) .
60

sources such a s

With the use of high energy

Co gamma rays, s kin reac tio ns a re usually minima ! ,

whereas with kilovoltage x-rays (orthovoltage ) int ense s kin reactions
may be noted.

Two to four weeks follol<in g radia tion is the period of

most intense skjn reactions.

At l ow rad iation doses, erythe ma, pigment

loss, ane dry desquamation may develop.

squamation a nd late necros is may de velop .

At higher doses, moist de-

The area affected in skin

r eactions usually conforms with the field size used during the treatmen t.
Dryness of the mou th and throat i s a common complaint of patients

receiving head and neck radiation.
accompany the dryness.

Difficulty in swallowing may

Thrush may develop within the mo uth following

irradiation wit h 60Co or x-ray .

The dryness i s due to the radiation

effects on the salivar y gl ands.
Salivary gIQp.d~ are classi fi ed as highly radios ensitive organs
because o f the rapid effect r aci iat ion has on thei r function.

But,

since epithelial gl a nds divide onl y rarely, the saliva ry glands could
be expect ed to be radioresistant (18).
As early as one day post-irradiation , t he salivary gland s may
show rapid and ma r ked swelling.

This effect may be ac~o unted for by

the c hanges in the e ndothelium of the vasculature, congestion and in-

creased permeability of capillaries, interstitial ede~a and ac ut e
infl ammatory cell i nfiltratio n, narrowing of the excretory duct due to

edema and inflammatory pressure, swelling of duct linings or plugging of
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lumina by mucous.

These chan g~ s could stop or al ter the function of

the sa livary glands.

Necrosis and cell degene r a tion may be a c o nse-

quence.

Hu,", " ,.aliva r y glands s urgically removed 24 hours following singl E
doses of radia tion show a parallel be tween the location and degree o f
a cut e inflammatory cell infiltration and ce ll degeneration.

These two

changes occur mostly in the serous cells and a re conside r ed dosedependent.

Inflammatory infiltration includes inva 31.on

l..:.

pt;.lymorpho-

nuclear leukocytes, eosinophilic leukocytes, and plasma cel ls along the

septa and around acini (alveoli).

Sometimes l umina appear to be full

of exudate from degenerating leukocytes a nd acinar cells.

Degene rative

vascular chan ges appea r in the cells, produc ing vagueness in acinar
outline and cleavage of the cells from their basement membranes.

Pyknosis is present.

Zymogen granules pool in acini and some gl a nd s

show a decrease in zymogen granules.
The ~rimary damage seems to occur in the s e r ous cells, although the
mechanism of tissue r eac tion is not known .

It may be tha t serous se-

cretion (with the enzyme a mylase) could enter capillaries allered by
radiation causing the inflammatory response noted earlier since there
are capillaries between se ro us acinar cells and not in mucous cells.
Henc e the serous epithelia l degeneration could be a secondar y ef fect of
radiation.

The lack of mucous cell dege ner&tion could be due t o the

fact that the muco us secretion does not enter the a ltered capillaries

if indeed this is the case.
The changes mentioned above fo :· single doses also appear i f the
radiation is delivered in fractionated doses, but the changes develop
progressively.
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Ac i nar ce l ls show

transi~nt

o r abor t i ve signs of secretion or

mitotic regene ra tion, bu t these are f ollowed hy progressive degene rative proce sses .
lost earlieL by

Reco ve ry of duc ts is us ually mo re marked.
t"

mit otic u~tivity .

.! xc r e torJ ducts. fo r examp le I aX l

The e xcretory duc t epl I.e i , ~ :

The re ll tl

. J ~ce d by

V laL e r shu ,,",
"

s quamous

D' ~ t al

may be product

s i a or
b~

the inter

Functiona l '.~ nefticient acin i

fa,

t Yr~r ~

~ l a te d

duct s as ac ini a re progres s ively

lost.
The sal ivary glands a re firm, smal l e r than normal , and s trongly
adherent t o the sur roundin g tis s ues a t the end of the ac ute clinical

pe riod,

The main his toi ogica l changes at th e end of this pe riod in-

elude : (1) i nterlobula r fibrosis, ( 2) int e r s titia l fibrosis and sc ler osis with i nfiltra tion of inflamma t o ry c e lls, (3) loss and

a tr~ ph y

or i nvolution of acini, (4) foci of necrosis in acini , and (5) metaplasia,
There are thrpe major pairs of sal ivary gland s in a l

mammals (19),

These compound tubulo- alveo12r glands a r e known as (1) pa rotid, (2) sublingual , and ( 3) s ubmandibula r,
serous and mucous cells.

of the serous type.

Th e salivary glands are composed of

The parotid

gland a ar e composed entirely

Although the submandibular and sublingual gland s

a r e both mixed glands (s e r ous and mucous) , th e submandibular glands
are a lmos t a ll se r o us, whereas th e sublingual glands are almost entire ly mucous.

The t ypic al gland consists of a secretory portion, the

alveolus, connected to a system of tubes which termI nate with an open-

ing in the oral cavity (3).

Connective tiss Je septae run through the

gland separating groups of alveoli into gland lobules.

Narrow channe ls,

the i nt ercalated ducts which are composed of cuboidal ce lls, lead
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directly f rom the alveoli.
While these ducts a r e long in the parotid glands , they are s hort in
the submandibular and sublingual glands and even sometimes absent 1n

the sublingual glaM ..

Numerous infoldings of the basal part of the

cell membrane, assoc ia teo with mitochondria, forms the striated ducts

which leud from the intercalated ducts.

Striated ducts lead to the

l a r ger interlobula r ducts whic h lead to the intralobular ducts which in
turn unite to form a single , terminattng excre tory duct composed of

columnar epithelium .

Toward the opening of the exc r e tory duct in the

o ral cavi ty, the ep ithelium becomes pseudostratified.
The excretory duct of the parotid gland opens into the vestibule of
the mouth just opposite the second molar tooth .

The excretory duct of

the submandibular gland opens near the side of the frenulum of the
tongue .

Parts of the sublingual g land open into the exc r eto ry duct of

the submandibular while other parts open through a single excretory
duct near the opening of the submandibular gland .
The secretory cells of the glands are both mucous and serous.
Zymogen granules, intracellular concentrations of ptyalin, give the
cytoplasm of serous cells a granular a ppearanc e .

is found toward the ba c.al end of the cell .

The rounded nucleus

The basal end of the cell is

strongly basophilic due to a high content of RNA .

Associated with this

area are the ribosomes of the endoplasmic reticulum which produce s the

protein of the

z>~ogen

gr anules (24 ).

The cytoplasm of the mucous cell stains very lightly when stained
with hematoxylin a nd eosin.

The mucinogen (pr ecursor of mucin) con-

tained within che mucous cell gives the cell its characteristic I'emp ty"

look upon staining.

Usually this mucinogen is lost during preparation
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for staining, hence the cytopla sm has a vacuolated appearance.

The

nucl eus of the mucous cel l is flatteued and close to the base of t he

cell .
A goo

"'.ood supply f urnis hes the salivary gland s their nourishl!1ent.

.

The I aeger vesse ls are found in the septae between the lobes and a

capillary plexus forms around the a lveoli.

Both

sy~a thet ic

and pa ra-

s ympathetic nerves innervat e the salivary glands.
The mucous cells secrete mucin which is a

~lear,

viscous substance.

Secretion of serous cells is thin and wa tery consisting of an
lyte solution.

~lectro -

The parotid gland secretes ptyalin, an amylase r e-

sponsible fo r splittin g sta r ch and glycogen enzymatically into maltose .
Upon stimula tion of e ither th e s ympa the tic and parasympathetic nerves, a
flow of "juices" is produced.

Nerve stimulation also increa ses the

flow of blood to the glands (21).

+

+

-

Saliva contains elec troly t es with

the main ones being Na , K , HC0 , and CI.
3
is

usuall ~

The composition of saliva

related to the nature of the food eat e n .

Approximately one liter of saliva is produced daily by man .

The

submandibular glands produce two- thirds of thi s amount, the parotid
glands produce one-fourth with the remainder produced by the sublingual
and other

sm~ ll

glands (buccal).

Saliva may be modified by the striated

ducts with their secretion of water and inorganic salts.
portant for aid in swallowing and tasting food.
oral hygiene .

Saliva is im-

It also helps maintain

Salivary glands play an enzymatic role; for examp le,

ptyalin, mentioned earlier.

An antimicrobia l role is also attributed

to saliva, probab l y be cause of the t hiocyanate ion present.
The salivary glands have been shown to have a high concentration of

WR-272l following administration of the compound.

The salivary glands
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are nearly always involved during t he radiotherapy of head and neck
tumors .

WR- 272l has been shown to afford a high radioprotective effec t

to some normal tissues while providing only minimal protection to the
tumo r; this

E.

''''.:5 to be relat e d to dif fe r ent, conc entrations of the drug

in the two diffe r ent tis s ues.

This s tudy is concerned with the evalu-

a tion of this drug for the possible radioprotection afforded to t he
salivary glands , skin, and oral mucosa of the o ral cavity .

f~Tr.RIAL S ~~ ~ffiTHODS

Mice we re used to study the oral radiation dea th syndrome and the

effects of radi ation on the histology of the salivary glands with and
without WR-272l.
Balb/c.

All mice used were female, white, and of inbred strain

They were purchased a t the age of 5-7 weeks from the Texas

Inbred Company, Houston, Texas.

The mice were not used for experiments

until they ~e r e at least 7-9 weeks old.

All mice were housed in 29 cm

long x 18 cm wirle x 12.5 cm high polystyrene cages.
watered ad libitum.

They were fed and

The average weight of the mouse was 20 grams.

The mice were divide d into two major groups for the oral radia tion
death study .

One group received WR- 272l (supplied by Dr. Melvin Heiffe r,

Walter Reed Army Hospit al , Washington, D.C.) and radiation while the
other group received only radiation.

The drug-treated (experimental)

group was anesthesized with 0.05 mg Nembutal Sodium Solution, U. S.P .
(sodi um pentobarbital, 50 mg / ml) injec ted intraperitoneally (Jelco
sterile, disposable syringes with Jelco sterile, disposable 25 gauge,
5/8" bevel needles) 45 minutes prior to radiation.

Fifteen minutes

later (30 minutes prior to radiation) this group was injected with
500 mg/kg WR-272l intraperitoneally.

The drug was dissolved in

Bacterio static Sodium Chloride Injection, U.S.P. (Ambot Soluti ons)
and filter sterilized by suction filtration through a 0.20 micron plain
membrane Nalge filter unit just prior t o injection.

The non-drug-

treated (control) group was injected with 1.0 mg Nembutal intraperitoneally 30 minutes prior to radiation treatment.
20
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Both control and experimen t al groups r eceived 60ro radiation. to
the head only, using a 28 cm x 28 cm field blocked off with lead (0 . 20
cm thick) to produce a 4 cm x 20 cm field and a source- to-skin distance
(550) of 65 cm .

The mice wer

1

radiated a t a rate of approximately

295 rads/min with a Zoneguard Picke r V-9 60Co model with a f factor
(roentgens/rads) of 0.957 , displacement factor of 0.985, chamber co rrection factor of 1.026. and a s tem correction fac tor of 1.0009 (when
calib rat ed at 8 em x 8 em) .
The experimental mice were divided into groups of ten each and were

irradiated with 100 rad increments for each successive group f rom 30003700 r ads .

The control mice we.e also divided into groups of ten each

and were irradiated with 100 rad increments for each successive group

but ranging from 1200-1800 rads .
Following radiation the mice were observed for deaths for a period
of two weeks.

Those deaths occurring from day 0-2 following radiation

treatment were rela t ed to to ."icity and thes e animals were not used in

the study.

The per cent dead was

the method of

Litchfi~ld

plott ~ d

against radia tion dose and

and Wilcoxon (13) was applied to det ermine the

LOSO/8-10.
Mice used for examinat ion of histological r adiation effects on
salivary glands were divided into two groups.

One group received

500 mg/kg WR-2721 and radiat ion while the other group received only
radiation.

The mice were irradiated in the same manner as previously

described for the oral radiation death study.
Mice were sacrificed with an overdose of ether at different time
intervals following radiation:

1 day, 1 week, 2 weeks, 3 weeks, 1 month,

2 months, 3 months, 4 months, 5 months, and 6 months.

Salivary glands
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were excised and placed immediately in Bouin's fixative.

After being

in the Bouin' 5 fixative for 4 hours, the glands ",'ere transferred into

70 per cent ethyl alcohol for an indefinite period of time in excess of
15 minutes.

Dehydration was c~r" ·. ted with three changes of 95 per

cent ethyl alcohol for 15 minute s each followed by three changes in 100
per cent ethyl alcohol for 15 minutes each.
The tissue blocks were then cleared in two changes of chloroform

for 15 minutes each.

After clearing, the glands were infiltra ted with
0

two changes of Paraplas t paraffin (melting point of 56-57 C) for 15
0

minutes each in a Preiser Thelco Hodel II 17 heating oven (5 7 C) .

This

was followed by infiltra tion in a nother change of paraffin f or 15
minutes in a Labline Vacuum Oven (16-24 inches water vacuum).

The hardened blocks of tissue were sectioned both longitudinally
and transversely into 5 micron sec tions with an AO Spencer "820" rotary
microtome.

The sect i ons were allowed to fa ll into a water floatat ion

bath maintained at 44-45 0 C.

Tc e sections were then put onto albuminized

(Hayer's Albumin Fixative) gl ass slides .

These gl a ss sl ides were then

rlaced into a heating oven a t 57 0 C and al lowed to stay until the paraffin melted.
The slides were then placed into three changes of xylene for 2
minutes each and then the t issue sections were rehydrated with absolute

e thyl alcohol , 95 pe r cent ethyl alcohol, and finally water.

Rehy-

dration steps consisted of three changes of each of the above solutions

for 2 minutes each.
After rehydration, different sections from the same tissue block

were stained using three different stains: (1) hematoxylin and eosin,
(2) Hasson-trichrome, using aniline blue as the counterstain, and
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(3) mucicarmine, usin g freshly made ~ucicarmin e ? repared by the
modified Mayer's method (8); the r.egular Mayer ' s method was then
used (14).
Aft e t" s a i nin g was c

,.. L ed t g las s cover sl ips we re applied with

lar l eco SJ'nthet .!.c Resin MOllntj ue i'!cciium.

The sect:ioned s alivary gland

preperations \ver.e then examined with li gh t microscopy.
Dogs wer i! ..!t:;o;;od t o st udy the effec ts o f radiation on salivary
functi '

<kin, ,,~,~ oral mucosa with and without WR-2721.

and male

.,,:~gr e l dogs were used.

Both female

They were mai:.tained on ad libitum

feeding in ,29 cm long x 9' em wide x 74 em high aluminum-barred pens.
The "'/~rage weight of th e do gs us ed was ap proximately 18 kilograms .
Eight do gs were divided into four g roups of t wo dogs each.

One dog

from each group received radiation and llR-2721 while the other dog rec e ived only radiation.

Both non-drug-treated (control) and drug-

treated (experimental) dogs were anesthesized with 26 mg/kg veterinary
grade Nembutal (60 mg/ml) injected intravenously (20 gauge, 1 1/ 2"
bevel needles) prior ~o radiation.

The experimental dogs were injected

intravenously with 70 mg/kg WR-272l 30 minutes prior to radiation .

The

drug was dissolved just before use and filter sterilized as described
above .

Both control and experimental dogs received radiation, to the left

side o f the head only, us ing a 16.5 em x 20

Cl"

tield blocked with lead

(0.6 cm thick) to a field of 8.25 em x 10 em, thereby excluding rae iation to the right side of the dog .

During the r adiatiop treatment the

dog was placed in a supine position with the bott0m of the lower jaw
facing the x-ray radiation tube.

The dogs were irradiated with a SSD

of 50 em at a rate of approximately 122 rads/min using a 20 milliamp,
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280 kilovolt powe r Picker X-Ray (Orthovol t age ) machine with a f factor
of 0.948, half-va lue laye r of 1.32 rom copper , a nd an effective ene r gy of
88 . 5 ki l o-elec tron volts.

Li thium fluoride chips were placed inside

th e cheeks of both the ri gr .

,I

d left sides of the dogs and the doses

of radiation were verified with a Victo r een 2800 Thermoluminescent
Dosimeter Reader .

dose of radiation.

Each of the fo ur g roup s of dogs r eceived a sin gle

The doses ranged f ro m 1000 t o 2500 rad s at 500 rad

increme nts.
Post-il"t il.!l a t ion saliv ary g1£.. :':' sec r etions were measur~ci a t weekly

intervals for one month fOLlowing radiation.

Measure~ent s were t aken

for both the right (non-irradia t ed) and left (irradiated) sides o f both
the cor-tral and e xp e riment a l groups .

The measuremen ts were t aken with the do gs in s upine positions under

Nembuta l anesthesia.

The mouths of the do gs were fi rst dried with

gauzes, then pre - we ighed Curity gauzes we re placed in the buc cal

pouches of both the right 3nd left s ides .
lin gually .

Ga uz es were also placed sub-

The mouth was ti ed loosely with a gauze .

Pro s t igmin 1:2000

(0.5 mg/ml) wa s injected intravenously a t a. do se of 1.0 mg per do g .
gauz es were removed 15 minut es later and r eweighed .

The

The difference in

the gauze weight before and af t e r salivary collec tion was used to repre-

sent salivary flow from the right and left buccal pouches.
gauzes were discarded.

Sublingual

Th e se co llec t ed f l ows were pl ot t ed as a function

of the time following radiation.

Photograph s we r e ~aken with a

Ni kkorma t FTn camera, using Kodak Ektachro me-X ASA 64 color slide f ilm,
to r eco rd t he acute reactions of the ha ir, skin , and oral mucosa.

RESULTS
The LD50 /8-10 f or t he control group of mice was calculated t o be
1600 r a ds (Figure 5) . wtereas the LD5U/B- 10 f ~ r the experimental group
of mice wa s found to be 3354 r ads (Figure 6).

The dose modifying

fac t o r (D~rr) is 2. 1. calc ula t ed as the ratio o f the LD50 experimental
to the LD50 contro l gr oup .
T3e toxic effec t of c ombined Nembutal and WR-27 2l was gr eat in the
mice .

It was found tha t the amount of Nembutal required for anes thes ia

in the experimental group was one-half t he amount r eq uired to anesthesize

t he cont r o l group.

The radiation dose of 2000 rads r es ulted in early dea th of all
con trol mice and histological comparison at this r adia t i on dose could

not he made.

Comparison of sa liva r y gl and s i rradia ted with 1000 rad ~

i n the contro l and experimenta : mice s hows s imilar histological changes

in the serous gl and s (Table Ill).

Mi ld degenerat ion ap pea rs as ear l y as

day one, progressing to early r egener a t ion of t he serous portion be-

ginn ing at week two .

Full r egenera t ion of the serous portion appears

t c no t be completed a t six month s fol l owing trea t ment .

Patchy a r eas of

normal se r ous c ells and o the r areas of sever e disor ganization are seen

in both gr oup s .
The muco us glands in the control group s how mild radiation damage
af ter one month and full r ecovery appears a t s i x months.

In the e xperi-

mental group. 1000 rads fails to produce any apparent damage to the
mucous ce lls t hro ugh the s i x month pe riod.
25
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Figure 5.

Oral radiation death without radioprotection showing the
LD50 /8-l0.
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Figure 6.

Oral radiation death with radioprotection showing the
LDSO/8-l0.
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TABLE III
RADlATION HISTOLOGY OF SEROUS GLANDS AFTER RECEIVING 1000 RADS

---------------1----------------------- --------- ----------- ------------I
I

WITHOUT WR-2721 i :lr. ~ Remarkabl e
WITH WR-2721
I Not Remarkab l e

---------------t------------------------------------- ------------------ONE WEEK
I
WITHOUT WR-27211 Some Degenerative Changes; Some Lack of Organization
WITH WR- l 721
I Some Degenerative Changes; Some Nuclear Hyperchromatism
I

---------------t--------------------------------------------------------

I
TWO \.'EEKS
WITHOUT WR- 27211 Cellular Hyperplas ia; Some Degene rative Changes;
I Hyperchromatic Nuclei
WITH WR-2721
: Cellular Hyperplas ia

---------------+-------------------------------------------------------:
THREE WEEKS
WITHOUT WR-2721: Not Rema rkabl e
WITH WR-2721
I Some Degenerative Changes

---------------+-------------------------------------------------------:
ONE HONTH
WITHOUT WR-2721: Not Remarkable
WITH WR-272l
: Not Remarkable

. ._------------+--------------------------------------------------------

:
TWO HONTHS
WITHOUT WR-272l1 Cellular Hyperplasia; Degenerative Changes; Nuclear

I

\'~TH

WR-2721

Hyperchromatism

: Cellular Hyperplasia; Nuclea r Hyperchromatism

---------------+-------------------------------------------------------I
THREE HONTHS, EIGHT DAYS
WITHOUT WR-272l: Hydropic Degeneration; HYDerchromatic Nuclei
IJITH WR-272l
: Cellular Degeneration ; Hyp e rchromatic Nuclei

---------------t-------------------------------------------------------FOUR HONTHS, ELEVEN DAYS
I
I

WITHOUT IJR-27211 Hydropic Degenera tion; Hyperchromatic Nuclei
IHTH WR-2721
: Cell ular Degeneration; Celblar Hyperplasia; Nuclear
I
I

Hyperchromatism

- - --- - ---------~------------------------------------- - - ----------------:
FIVE HONTHS
WITHOUT WR-272l1 Hydropic Degeneration; Large, H"perchromatic Nuclei
WITH WR-2721
: Some Hydropic Degeneration
---------------~ ----- --------------------------------- --------------- - - I
SIX HONTHS
WITHOUT \'~-2721: Cellular Hyperplasia; Nuclear Hyperchroma tism
WITH WR-272l
I Cellular Hyperplasia; Nuclear Hyperchromatism

---------------~--------------------------------------------------------
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Preliminary baseline salivary flows were incons i Stent in all dogs.
The POst-radia tion saliva measu r ements of both Control and eXperimental
dogs do not s how any consiste nt flow patterns (Figures 7 through 10).
The r e is a general trend ho. eve r of lesser saliva ry seC r e tion from the

l e ft Side of both Control and e xperimental dogs.
There was a loss of pigment in the left bUccal Pouches of both

Control and experimental dogs with the
month fOllowing radiation.

maxj~um loss

ocCurring at

O~e

There Was almos t to tal los s of Pigment in

the Control dog (Figure 11) followe d by full restoration of pigment
Within two months folloWing radiation (Figure 12).

Loss of Pigment in

the experimental dog was very Slight one month fOlloWing radiation
(Figure 13) .

This was also fallow ed by full restoration of Pigment

Within two mon t hs fOlloWing radiation (Figure 14).
The oral cavity strUCtu res at no time shOwed radia tion damage

fOlloWing 1000 rads.

Ve ry minimal hair l o ss occurred at this low dOse

t n the Control animal, wherea s the re was no hair loss in the expe rimen tal
dog.

MOderat e hair l oss occurred a t 1500 rads in the Control dog a t two
months, Whereas there was no lo s s of hair in the dog receiVing the drug.
There Was no hair lo ss in t he experimen t al dog two •• onths folloWing
treatmen t with 2000 rads (Figure 15), Whereas the control member of the
pair had total hair loss at

th~t

time (Figure 16).

MOist desquamation of the skin occurred a t the 2500 rad level in the

Co ntrol animal.
2500 rads.

Figure 17 Shows the Control dog two weeks fOllOWing

Figure 18 shows the same dog with mOist desqUamation one

month fOlloWing 2500 rads .

Figure 19 shows the experimental dog two

weeks fOlloWing 2500 rads .

Figure 20 shows the same dog with only
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Figur ~ 7.

Salivary secretion measurements by weight following 1000 rads
of x-ray (orthovoltage) radiation.
Legend
----- Without WR-272l
- - With WR-272l
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Figure 8 .

Salivary secretion measurements by weight following 1500 rads
of x-ray (ort hovoltage) radiation.
Legend
----- Without WR-2721
- - With WR-2721
o

Right Side

f1

Left Side

-.... .

-,...

.-

...

... ~---

ao

1500 rads

7.0

6.0

-•. 5.0
a

~

OIl

~
~

4.0

,,
,

o------q.

C(

>

....I

CC
en

3.0

4..,

""

"

2.0

"~ "

" --..,

,

'''~

1.0

o?
Radiation

2

WEEKS

3

4

~

........

-

32

Figure 9.

Salivary secretion measurements by weight following 2000 rads
of x-ray (orthovoltage) radiation.
Legend
----- Without WR-272l
- - With WR-272l
o
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Figure 10.

Salivary secretion measurements by weight following 2500 rads
of x-ray (orthovoltage) radiation.
Legend
----- Without WR-2721
- - With WR-2721
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Figure 11.

Left buccal pouch showing example of pigment loss in control
dogs one month following x-ray (orthovoltage) radiation.

Figure 12 .

Left buccal pO'Jch showing example of restora tion of pigment
in control dogs two months following x-ray (orthovoltage )
radiation .
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Figure 13.

Left buccal pouch showing example of little pigment loss in
the experimental dogs one month following x-ray (orthovoltage) r adiation.

Figure 14.

Left buccal pouch showing example of restoration of pigment
in the experimental dogs two months following x-ray (orthovoltage) radiation.
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Figure 15.

Experimental dog two months followin g 2000 r a ds of x- ray
(orthovolt age ) r adiation showing no hair loss.

Figure 16.

Control dog two mo nths following 2000 rads of x-ray (orthovoltage) radiation showing total hair lo ss of the left
(irrad i ated ) s id e .

.--

·a
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Figure 17.

Control dog two weeks f ollowing 2500 r ads of x-ray (or thovoltage) radiation.

Figure 18.

Control dog one month following 2500 rads of x-ray (orthovoltage) r adiation showing moist desq uama tion of the skin.
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Figure 19.

Experimental dog two weeks following 2500 rads of x-ray
(orthovoltage) radiation.

Figure 20.

Experimental dog one month following 2500 rads of x-ray
(orthovoltage) showing moderate hair loss on the left
(irradiated) side .
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moderate hair loss one month following 2500 rads.
The ora l mucosal r eac tions were consistently grea ter in the control
animals .

radial.

The maximum acute r r.actions occurred at two weeks following

n.

Animals r e ceiving Iffi-2721 had faster healing of the effects

of radiation .
Fjgu~es

21 through 24 show the oral mucosal reactions of the

control dog following treatment with 1500 rads.

The experimental dog

showed only a very slight reaction, similar to that seen in Figure 23,
which appeared at two weeks following radiation and was gone by three
weeks.
w~eks,

The reaction in the control dog was s till present at three
but it was gone by four weeks following radiati on.

The oral macosa of the experimental dog receiving 2000 rads showed
a larger reac tion, than the do g receiving 1500 rad s alone, at two weeks

following radiation (Figure 25).

All the oral mucosal radiation re-

action in the experimental dog receivin g 2000 rads was gone by one
month following radiation (Figure 26).

The control dog showed a much

larger radiation reaction, covering the entire area of the oral mucosa

irradiated, two weeks following radiation (Figure 27).

A slight re-

action was s till present at one month followin g radiation (Figure 28).
Following 2500 r ads the cont ro l and experimen tal dogs showed similar reactions of the oral mucosa with the reac tion covering the total
a r ea irradiated.

But the react ion oc ~ urred a t one week in the control

dog and did not occur until two weeks in the experimental dog.

Figure 29 shows t he reaction in the control dog one week following radiation.

Figure 30 shows the rea c tions st11l present at four weeks

following radiation .

Figure 31 shows the reaction in the experimental

dog at two weeks following radiation.

Figure 32 shows the reactions
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gone by three weeks following r a diation.

A s imilar oral mucosul re-

action e ff ec t occurr ed at 2500 r ads in the drug-trea ted animal and at
1500 r ads in the non-drug-treat ed cnimal .
a tion doser , {ves a DMF of 1.67.

The r a tio of these two radi-
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Figure 21.

Oral mucosa "of the tongue in the control dog one week

following 1500 r ads of x-ray (orthovoltage) radiation .

Figure 22.

Oral mucosa of the tongue in the control dog two weeks
following 1500 rads of x-ray (orthovo1tage) radiation.
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Figure 23.

Oral mucosa of the tongue in the control dog three weeks
following 1500 rads of x-ray (orthovoltage) radia tion showing only a small area of rad ia tion reaction.

Figure 24.

Oral mucosa of the tongue in the control dog one month
following 1500 rads of x-ray (orthovoltage) radiation.
~lucosa is free of any radiation reaction.
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Figure 25.

Oral mucosa of the tongue in the experimental dog two weeks
following 2000 rads of x-ray (orthovoltage) radiation.

Figure 26.

Oral mucosa of the tongue in the experimental dog one month
foll ~wi n F 2000 rads of x-ray (orthovoltage) radiation.
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Figure 27.

Figure 28.

Oral mucosa of the tongue in the control dog two weeks
fol l owing 2000 rads of x-ray (orthovoltage) radiation .

Oral mucosa of the tongue in the control dog one month
following 2000 rads of x-ray (orthovoltage) radiation.
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Figure 29 .

Oral mucosa of the tongue of the control dog one week

following 2500 rads of x-ray (orthovoltage) radiation.

Figure 30.

Oral mucosa of the tongue of the control dog four weeks
fol lowing 2500 rads of x-ray (orthovoltage) r adiation.
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Figure 31.

Oral mucosa of the tongue of the experimental dog two weeks
following 2500 rads of x-ray (orthovoltage) radiation.

Figure 32.

Oral mucosa of the tongue of the experimental dog three
weeks following 2500 rads of x-ray (orthovoltage) radiation.

DISCUSSION

Even thou gh the reason for th e oral radiation death syndroit.'. 1s not

known, a DMF of 2 .1 could be of great significance .

This syndrome,

which has been described only in mice (9), has been modified to a
larger degree by 1,JR-2721 than any protective compound previously
studied.

This death point (ora l radiation death) may have little si g-

nificance in large animals, but it prevented the study of the effects of
large doses of radiation on the histology of mouse salivary glands, as

originally planned .

The desire to use mice for the study of the effects

of radiat ion on salivary gland histology stems from the fact that use
of these s mall inbred animals would allow comparison studies of large

numbers of genetically identical animal s .

Histological evaluation of

salivary glands in this study is th erefore limited to low radiation
dose i n mice for acute and later changes.

Higher doses can be evalu-

ated in mongrel dogs .
The sali vary gland ma y be an organ for e xcretion or metabolism of

WR-2721 which could explain the lack of protection observed in the
salivary s e rous glands .

It is apparent that the mucous glands are rel a-

tively radioresistant because only mild radiation damage, follo~ed by
full regeneration, was observed in the control mice .

This is also ob-

served clinically in patients receiving radiation to the salivary
glands .

There is a quick reduction in the serous secretions, leaving

the patient with thick mucous secretions (26).
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Physiological c hanges in bo th the cont~ol and exper imental dog
salivary glands were small er than expec t ed .

The radia tion doses given

far exceeded the equivalent doses used in human radiation therapy .
SalivarY l ~ c retlon from the irradiated glands in both expe riment a l and
control animals however continued, al though at decreased l eve l s.

Pos s i ble problems with this s tudy might include:
1.

Ther e is unusual radioresistance of dog sal ivary tissue
as compa r ed t o human salivary tis sue.

2.

The method of saliva collection was inadequate.

3.

Less than the intended dose of r adia tion was delivered .

4.

Diurnal variation masked the resul t s.

5.

The high concentra tion of 355 WR-27 2l seen in the autor adiographs of the salivary gland s represents excretion

of this drug, similar to excret i on obse rved in the kidney (25).
It i s mos t likely tha t the salivary gland is another or gan of exc r e tion fo r WR- 2 72l.
would be expected.

If this is true, then po s sibl y no pro tection
The kidney a l so shows high concentrations of

35 5 WR-272l, but i t is not protected by the drug.

The kidney merely

exc r etes the drug.
It is fe lt that th e method of saliva measurement s was adequa t e .

The mo uth was dried with gauz e before insertion of pre-weigheJ gauzes .
Ga uzes we r e also placed su~lingually t o prevent the saliva secreted
the r e from draining on to the pre-weighed gauzes in the buccal po uches .
Since the gauzes used in the pouches did not become supersaturated and

the mouth was qui te dry after they were remo ved, it seems the full
amount o f saliva secreted was obtained.

Both lithium fluoride dosimetry and the r adiation changes observed
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in the skin and o ral cavity indicate the actual doses delivered wer.e
the planned radi a tion doses.
Preliminary sa liva r y sec r e tions wer~ ,;ol lected 1 0 th in early
mornin g and

I'

late evenin g , with the dogs on ad libitum feeding, and

twelve hours witho ut food .
manipula tions.

No pattern CQulJ b~ found af t er these

Thi- mongrel dogs of cours e cO'j Id

:Jt

be compa·r ed

with each other in t he sam(' mann~r as inb r ed mice were compa:Y:'eci .
Protec t ion of the skin and oral mucosa \las readily apparent at two

to four weeks in do gs r ece iving doses hi gher than 1000 r ads .

The end

point for comparison between the con tro l and the experime nt al animals
that was c hos en was that effect which would be clinical ly acceptable.

Al t hough there was pr otection against moist desquamation a t the 2500 rad
level , this condition is rarely observed in clinical radiothe ra py unless

bolus mate rial for e lectron build-up is placed dire ctly on the skin .
The total-hair- loss end point resulted in a DMF of 1. 67.

Higher

DMF ' s of 2 . 0 and 2 . 4 have been reported for skin pr ot ect i on (17, 30),
the r efore problems wi th thi s study mjght include:
1.

The period o f thirt y w.inu t es between i nt ravenous injection
of the drug and r adiation was too long.

This time period

was chosen t o a llow gr eater concentra tion of the drug in

the salivary gl ands.

Autoradiogr aphic stud ies of

35 5 ~~-272l shows th a t the skin cl earing of the drug's
.
r ap i d (25), therefo r e , higher DHF ' s for skin a nd oral
mucosal protection might have been obtained if the radia tion had been delivered 5-10 minutes f ollowing the drug
injection.
2.

Large field sizes in large animals have not been studied
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previously fo r skin protection.

It is possible that the

protective effec t might be gr ea t e r when smal l e r areas are

irradiated.
3.

The orthovol t age mach '....

used in this s tudy wou l d be

expected t o produce a n igher r eac ti o n at t he skin s ur face
than megavoltage machines.

It seems that WR- 2 72l has a definite protec t ive ac tion against
ionizin g radiation in o r al cavit y s tructures .

Th e protection is g r ea ter

at lower r eaction gr ad es than at the high-do se e nd point of moist des quama tion .

It i s mos t probab l e tha t th e protective effect could be

greater if the time between the drug in je c t ion and r adia tion were l ess .
One o f the most cotmnon comp la ints of pa ti en t s r eceiving head a nd
neck radiation is a dry mouth due to the r adia tion damage t o the

salivary g l a nd s .

Although this d ru g in this s tud y was not shown t o pro -

vide protection of the salivar y ser ous g lands , i t does g i ve promise of

being use ful c l i ni ca lly .

The patient could possibly be prot ected f r om

the acu t e radia tion reactions of the skin and or a l muc~sa using WR-2 72 1 .

The toxicity noticed in the mice rec e iving ~emb ut a l and WR- 272l was
not apparent in the clogs .

This probab ly is re l a t ed to the s i ze of the

animal and the amo unt of WR- 272 l given.

Thi s would not be a problem

with human s, as the patien t is r a r e l y anesthes ized prior to radiot herapy.

Add it iona l investigations of the radiop r o t ec tive effect of WR-272l
a r e indicat e d on the basis of findings r epor t ed in t his study.
possible sugges tions for new st udies might include:

1.

The pro t ective effec t may be related to the fiel d size
of radiation .

Studies with diffprent field s iz e s could

theref ore prove to be va luable .

Some
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2.

The protective effect may be different wh~n diffe r ent
radiotherapy machin es are used.

An experi ment usin g

kilovoltage and megavoltage e nergies .o1ou ld the r efore
show differer......

3.

$

in protec tion .

The protec t ive eff e ct may be rela ted to the time bet ween the drug admini s tration a nd r adiatio~ .

Studies

which va r y t he times could show different D~W ' s at
specific end po ints.
4.

Diffe r ent rout es of adminis tra tion of the dr ug could
poss ibly show different prot ect ion against t he same r adio ion reaction .

Comparison between oral, in Lr ape r ito neal ,

to pical, and intravenous administ r a tions s hould be made.

5.

Finally. since this study s ugges t s that the salivary gland
may be another organ of exc r e tion of WR-2721, further
radiolabe lled WR-2721 st udies should be made t o help trace
the path of the drug administer ed sys t emically.

As th e informat ion about WR-2721 increase .. i t ougges t s tha t it woul d
be of value in clinical rc 'l.a tion therap y fo r the protection of normal
tissues from t he damaging e ffects of radiation.
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